Literature DB >> 2984638

Halopemide, a new psychotropic agent. Cerebral distribution and receptor interactions.

A J Loonen, W Soudijn.   

Abstract

Halopemide is a new psychotropic agent, a structural analogue of the neuroleptics of the butyrophenone type but with different pharmacological and clinical properties. Preliminary clinical findings indicate that halopemide lacks the ability to induce parkinsonism and may be an effective drug in the treatment of psychosis characterized by autism, emotional withdrawal or apathy. Its pharmacological effects at a molecular level in comparison to structurally related neuroleptics and putative metabolites are reviewed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984638     DOI: 10.1007/bf01962862

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  41 in total

1.  IS IT POSSIBLE TO PREDICT THE CLINICAL EFFECTS OF NEUROLEPTIC DRUGS (MAJOR TRANQUILLIZERS) FROM ANIMAL DATA?I. "NEUROLEPTIC ACTIVITY SPECTRA" FOR RATS.

Authors:  P A JANSSEN; C J NIEMEGEERS; K H SCHELLEKENS
Journal:  Arzneimittelforschung       Date:  1965-02

2.  Influence of GABA-agonists and antagonists on neuroleptic-induced catalepsy in rats.

Authors:  P Worms; K G Lloyd
Journal:  Life Sci       Date:  1978-08-07       Impact factor: 5.037

Review 3.  Biochemical pharmacology of GABAergic agonists.

Authors:  S J Enna; A Maggi
Journal:  Life Sci       Date:  1979-05-07       Impact factor: 5.037

4.  GABA-induced locomotor activity in the rat, after bilateral injection into the ventral tegmental area.

Authors:  T Tanner
Journal:  Neuropharmacology       Date:  1979-05       Impact factor: 5.250

Review 5.  Brain dopamine receptors.

Authors:  P Seeman
Journal:  Pharmacol Rev       Date:  1980-09       Impact factor: 25.468

6.  Effects of halopemide on GABA receptor binding, uptake and release.

Authors:  A J Loonen; C J Soe-Agnie; W Soudijn
Journal:  Brain Res       Date:  1981-04-06       Impact factor: 3.252

7.  Effects of halopemide, a new psychotropic agent, on the uptake of serotonin by blood platelets.

Authors:  A J Loonen; W Soudijn
Journal:  Arch Int Pharmacodyn Ther       Date:  1979-02

8.  Effects of neuroleptics on release of 3H-dopamine from slices of rat corpus striatum.

Authors:  K Dismukes; A H Mulder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-03       Impact factor: 3.000

9.  Inhibition by neuroleptics of uptake of 3H-GABA into rat brain synaptosomes.

Authors:  B Fjalland
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-01

10.  Halopemide and benzodiazepine binding sites.

Authors:  A J Loonen; C J Soe-Agnie; W Soudijn
Journal:  Arch Int Pharmacodyn Ther       Date:  1982-07
View more
  4 in total

Review 1.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

2.  Endocrine and neurochemical effects of (+)-PHNO, a dopamine D2 agonist.

Authors:  C M Gust; S K Hemrick-Luecke; R W Fuller
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

3.  Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.

Authors:  Amanda R Noble; Norman J Maitland; Daniel M Berney; Martin G Rumsby
Journal:  Br J Cancer       Date:  2017-11-14       Impact factor: 7.640

Review 4.  Targeting phospholipase D in cancer, infection and neurodegenerative disorders.

Authors:  H Alex Brown; Paul G Thomas; Craig W Lindsley
Journal:  Nat Rev Drug Discov       Date:  2017-02-17       Impact factor: 84.694

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.